Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,865 across all filing types
Latest filing 2016-06-17 Regulatory Filings
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Galapagos NV, for the month of June 2016. Form 6-K is used by foreign private issuers to report material information that is not required to be filed on Form 20-F or 40-F, often including press releases or other announcements. The document references an attached press release (Exhibit 99.1) but does not contain detailed financial statements or substantive financial data itself. The document length is short (1486 characters), and it primarily serves as a regulatory filing to report the press release. Therefore, it is not an Annual Report (10-K), Interim Report (IR), or Earnings Release (ER), but rather a Regulatory Filing (RNS) as a general SEC filing for foreign issuers' material information.
2016-06-17 English
Galapagos' R&D Update 2016
Investor Presentation Classification · 98% confidence The document is titled 'Galapagos' R&D Update 2016' and details clinical trial results (Phase 1 safety data for GLPG2222 and GLPG1972), pipeline progress (new preclinical candidates), and future R&D goals. It announces a webcast and conference call for investors to discuss these updates. This content strongly aligns with an Investor Presentation (IP), which typically covers strategy, pipeline, and recent scientific/clinical progress presented to the investment community. It is not a full Annual Report (10-K), a formal Earnings Release (ER) focusing only on financial metrics, or a simple announcement of a report (RPA/RNS). The structure and content are characteristic of an in-depth presentation to investors about research and development activities.
2016-06-15 English
Galapagos' R&D Update 2016
Investor Presentation Classification · 98% confidence The document is titled 'Galapagos' R&D Update 2016' and provides detailed updates on clinical trial progress (Phase 1 data, safety profiles, biomarker results) for several drug candidates (GLPG2222, GLPG1972, GLPG2938, GLPG2534). It also outlines future pipeline goals (Phase 3 initiation, PoC delivery) and announces a webcast/conference call to discuss this R&D strategy. This content is characteristic of an Investor Presentation (IP) or a detailed scientific/pipeline update, rather than a formal regulatory filing like a 10-K, an Earnings Release (ER) which focuses on financial metrics, or a simple Report Publication Announcement (RPA). Since it is a detailed presentation of strategy and pipeline data aimed at investors, Investor Presentation (IP) is the most appropriate classification.
2016-06-15 English
Galapagos' R&D Update
Investor Presentation Classification · 98% confidence The document is titled 'Galapagos' R&D Update 2016' and provides detailed updates on clinical trial progress (Phase 1 data, safety profiles, biomarker results) for several drug candidates (GLPG2222, GLPG1972, GLPG2938, GLPG2534). It also outlines future pipeline goals (Phase 3 initiation, PoC delivery) and announces a webcast/conference call to discuss this R&D strategy. This content is characteristic of an Investor Presentation (IP) or a detailed scientific/pipeline update, rather than a formal regulatory filing like a 10-K, an Earnings Release (ER) which focuses on financial metrics, or a simple Report Publication Announcement (RPA). Since it is a detailed presentation of strategy and pipeline data aimed at investors, Investor Presentation (IP) is the most appropriate classification.
2016-06-15 English
Galapagos R&D Update
Investor Presentation Classification · 98% confidence The document is titled 'Galapagos' R&D Update 2016' and details clinical trial results (Phase 1 safety data for GLPG2222 and GLPG1972), pipeline progress (new preclinical candidates), and future R&D goals. It announces a webcast and conference call for investors to discuss these updates. This content strongly aligns with an Investor Presentation (IP), which typically covers strategy, pipeline, and recent scientific/clinical progress presented to the investment community. It is not a full Annual Report (10-K), a formal Earnings Release (ER) focusing only on financial metrics, or a simple announcement of a report (RPA/RNS). The structure and content are characteristic of an in-depth presentation to investors about research and development activities.
2016-06-15 Dutch
Galapagos selected for AEX Index
Regulatory Filings Classification · 95% confidence The document is a press release dated June 9, 2016, announcing that Galapagos NV will be included in the AEX Index starting June 20, 2016. This type of announcement, which details a significant corporate event (index inclusion) but is not a formal regulatory financial report (like 10-K, IR, or ER), fits best under the general category for regulatory announcements or significant corporate news that doesn't match other specific codes. Since it is a formal announcement of a corporate event/change, and it is not a Director's Dealing (DIRS), Capital Change (CAP), or Delisting (DLST), the most appropriate general category for non-financial, non-meeting related corporate news announcements is 'Regulatory Filings' (RNS), which serves as a broad category for official company announcements not covered elsewhere. It is too specific to be a generic 'LTR' and does not relate to dividends, management changes, or shareholder votes.
2016-06-09 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.